Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The research will assess whether rocatinlimab can improve the condition of patients’ skin by reducing the severity and affected areas of eczema. The study will measure improvements in skin appearance, reduction in pruritus (itching), decrease in skin pain, and overall quality of life for participants. It will specifically examine whether participants achieve clear or almost clear skin on their face, hands, and other body areas after treatment.

Throughout the 24-week study period, participants will receive either rocatinlimab or placebo and will need to regularly report their symptoms and complete assessments. The research is designed for adults who have had atopic dermatitis for at least 12 months and have not responded adequately to previous treatments for their condition.

The purpose of the study is to compare the effectiveness and safety of Upadacitinib and Adalimumab against a placebo in people with moderate to severe rheumatoid arthritis. The study will be conducted in two periods. In the first period, participants will receive either Upadacitinib, Adalimumab, or a placebo to see how well these treatments work in reducing the symptoms of rheumatoid arthritis. The second period will focus on evaluating the long-term safety and effectiveness of Upadacitinib for those who complete the first period.

Participants will be monitored over a period of time to assess improvements in their condition, such as reduced joint pain and swelling, and to ensure the treatments are safe. The study aims to provide valuable information on how these treatments can help manage rheumatoid arthritis for those who have not had success with Methotrexate alone.

The purpose of the study is to evaluate the safety and tolerability of this treatment in children who have been diagnosed with nosocomial pneumonia. Participants in the study will receive the medication and be monitored for any side effects or reactions. The study will also measure how the body processes the medication, including how it is absorbed, distributed, and eliminated. This information will help determine the appropriate dosage and frequency for treating this type of pneumonia in pediatric patients.

Throughout the study, researchers will collect data on the participants’ health and any adverse events they may experience. This will help ensure that the treatment is safe and effective for children with nosocomial pneumonia. The study is designed to provide valuable insights into the use of ceftolozane and tazobactam in treating this serious infection in a hospital setting.

Participants in this study will continue taking darolutamide as they have in their previous studies. The study aims to monitor the safety of darolutamide and observe any side effects that may occur during the treatment. The study does not involve any new medications or treatments, and participants will not receive a placebo.

The study will track the occurrence of any treatment-related side effects, including both common and serious ones. It will also look at how often the dosage of darolutamide needs to be adjusted. This study is open-label, meaning that both the participants and the researchers know that darolutamide is being administered. The study will continue until the estimated end date in 2025, allowing participants to maintain their treatment regimen as long as they continue to benefit from it.

The purpose of the study is to test these treatments in a structured way to see how well they work and to gather information about their effects. The study will involve different phases where participants will receive these treatments over a period of time. The treatments will be given in various forms, such as oral suspensions, tablets, or injections, depending on the specific medication. The study will also explore the potential benefits of new types of treatments, such as immunotherapy, for certain groups of patients.

Throughout the study, participants will be monitored to assess the effectiveness of the treatments and to identify any side effects. The study will collect data on survival rates, the occurrence of any relapses, and the overall quality of life of the participants. This information will help researchers understand how these treatments can be used to improve outcomes for people with Acute Lymphoblastic Leukemia.